ARROWHEAD PHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense in USD from Q4 2011 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Arrowhead Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q4 2011 to Q3 2024.
  • Arrowhead Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $18.1M, a 0.37% decline year-over-year.
  • Arrowhead Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $67.1M, a 14.1% decline year-over-year.
  • Arrowhead Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $67.1M, a 14.1% decline from 2023.
  • Arrowhead Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $78.1M, a 35.4% decline from 2022.
  • Arrowhead Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $121M.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $67.1M $18.1M -$68K -0.37% Jul 1, 2024 Sep 30, 2024 10-K 2024-11-26
Q2 2024 $67.2M $14.7M -$5.24M -26.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $72.4M $16.6M -$4.03M -19.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $76.4M $17.7M -$1.7M -8.79% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-06
Q3 2023 $78.1M $18.2M Jul 1, 2023 Sep 30, 2023 10-K 2024-11-26
Q2 2023 $19.9M -$13.4M -40.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $20.6M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $19.4M Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-06
Q2 2022 $33.4M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q4 2017 $7.56M $2.09M -$332K -13.7% Oct 1, 2017 Dec 31, 2017 10-Q 2018-02-09
Q3 2017 $7.89M $2.01M -$2.04M -50.4% Jul 1, 2017 Sep 30, 2017 10-K 2017-12-12
Q2 2017 $9.93M $1.71M -$1.04M -37.7% Apr 1, 2017 Jun 30, 2017 10-Q 2017-08-03
Q1 2017 $11M $1.74M -$673K -27.8% Jan 1, 2017 Mar 31, 2017 10-Q 2017-05-03
Q4 2016 $11.6M $2.42M +$44.1K +1.85% Oct 1, 2016 Dec 31, 2016 10-Q 2018-02-09
Q3 2016 $11.6M $4.05M +$521K +14.8% Jul 1, 2016 Sep 30, 2016 10-K 2017-12-12
Q2 2016 $11.1M $2.75M +$265K +10.6% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 $10.8M $2.42M +$212K +9.6% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-03
Q4 2015 $10.6M $2.38M +$365K +18.1% Oct 1, 2015 Dec 31, 2015 10-Q 2017-02-06
Q3 2015 $10.2M $3.53M Jul 1, 2015 Sep 30, 2015 10-K 2017-12-12
Q2 2015 $2.49M +$1.42M +132% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 $2.21M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q4 2014 $2.01M +$1.49M +287% Oct 1, 2014 Dec 31, 2014 10-Q 2016-02-09
Q2 2014 $1.07M +$707K +194% Apr 1, 2014 Jun 30, 2014 10-Q 2014-08-12
Q4 2013 $521K +$125K +31.7% Oct 1, 2013 Dec 31, 2013 10-Q 2014-02-04
Q2 2013 $364K Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-12
Q4 2012 $396K +$144K +57.1% Oct 1, 2012 Dec 31, 2012 10-Q 2014-02-04
Q4 2011 $252K Oct 1, 2011 Dec 31, 2011 10-Q 2013-02-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.